In vivo tissue engineering of heart valves: Evolution of a novel concept

Regenerative Medicine

Volumn 4, Issue 4, 2009, Pages 613-619

  Scleicher, Martina ^a   Wendel, Hans Peter ^a   Fritze, Olaf ^a   Stock, Ulrich A ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Aptamer; Heart valve; In vivo; Off the shelf; Tissue engineering

Indexed keywords

APTAMER; MACROGOL; VASCULOTROPIN;

ARTICLE; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; ENDOTHELIUM CELL; HEART VALVE; IMMOBILIZED CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STEM CELL; TISSUE CULTURE; TISSUE ENGINEERING; TISSUE REGENERATION; BIOPROSTHESIS; CYTOLOGY; HEART VALVE PROSTHESIS; HUMAN; METABOLISM; METHODOLOGY;

APTAMERS, NUCLEOTIDE; BIOPROSTHESIS; ENDOTHELIAL CELLS; HEART VALVE PROSTHESIS; HUMANS; STEM CELLS; TISSUE ENGINEERING;

EID: 70349759089     PISSN: 17460751     EISSN: None     Source Type: Journal    
DOI: 10.2217/rme.09.22     Document Type: Article

References (56)

1. Peterseim DS, Cen YY, Cheruvu S et al.: Long-term outcome after biologic versus mechanical aortic valve replacement in 841 patients. J. Thorac. Cardiovasc. Surg. 117(5), 890-897 (1999).
2. Gao G, Wu Y, Grunkemeier GL et al.: Durability of pericardial versus porcine aortic valves. J. Am. Coll. Cardiol. 44(2), 384-388 (2004).
3. Brown JM, O'Brien SM, Wu C et al.: Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J. Thorac. Cardiovasc. Surg. 137(1), 82-90 (2009).
4. Vongpatanasin W, Hillis LD, Lange RA: Prosthetic heart valves. N. Engl. J. Med. 335(6), 407-416 (1996).
5. Hammermeister KE, Sethi GK, Henderson WG et al.: A comparison of outcomes in men 11 years after heart-valve replacement with a mechanical valve or bioprosthesis. Veterans affairs cooperative study on valvular heart disease. N. Engl. J. Med. 328(18), 1289-1296 (1993).
6. Mestres CA, Agusti E, Martinez A et al.: Cardiovascular tissue banking in the non-cadaveric setting: ten-year experience of a university hospital-based bank with active organ donation program. J. Heart Valve Dis. 9(4), 523-529 (2000).
7. Wetli CV, Kolovich RM, Dinhofer L: Modified cardiectomy: documenting sudden cardiac death in hearts selected for valve allograft procurement. Am. J. Forensic Med. Pathol. 23(2), 137-141 (2002).
8. Gulbins H, Kreuzer E, Reichart B: Homografts: a review. Expert Rev. Cardiovasc. Ther. 1(4), 533-539 (2003).
9. Mayer JE Jr: In search of the ideal valve replacement device. J. Thorac. Cardiovasc. Surg. 122(1), 8-9 (2001).
10. Langer R, Vacanti JP: Tissue engineering. Science 260(5110), 920-926 (1993).
11. Stock UA, Mayer JE Jr: Valves in development for autogenous tissue valve replacement. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu. 2, 51-64 (1999).
12. Steinhoff G, Stock U, Karim N et al.: Tissue engineering of pulmonary heart valves on allogenic acellular matrix conduits: in vivo restoration of valve tissue. Circulation 102(Suppl. 3), III50-III55 (2000).
13. Schenke-Layland K, Opitz F, Gross M et al.: Complete dynamic repopulation of decellularized heart valves by application of defined physical signals - an in vitro study. Cardiovasc. Res. 60(3), 497-509 (2003).
14. Sutherland FW, Perry TE, Yu Y et al.: From stem cells to viable autologous semilunar heart valve. Circulation 111(21), 2783-2791 (2005).
15. Gummert JF, Funkat A, Beckmann A et al.: Cardiac surgery in Germany during 2007: a report on behalf of the German society for thoracic and cardiovascular surgery. Thorac. Cardiovasc. Surg. 56(6), 328-336 (2008).
16. Breuer CK, Mettler BA, Anthony T et al.: Application of tissue-engineering principles toward the development of a semilunar heart valve substitute. Tissue Eng. 10(11-12), 1725-1736 (2004).
17. Dohmen PM, Costa F, Lopes SV et al.: Results of a decellularized porcine heart valve implanted into the juvenile sheep model. Heart Surg. Forum 8(2), E100-E104 (2005).
18. Bader A, Schilling T, Teebken OE et al.: Tissue engineering of heart valves - human endothelial cell seeding of detergent acellularized porcine valves. Eur. J. Cardiothorac. Surg. 14(3), 279-284 (1998).
19. Elkins RC, Dawson PE, Goldstein S et al.: Decellularized human valve allografts. Ann. Thorac. Surg. 71(Suppl. 5), S428-S432 (2001).
20. Gldstein S, Clarke DR, Walsh SP et al.: Transpecies heart valve transplant: advanced studies of a bioengineered xeno-autograft. Ann. Thorac. Surg. 70(6), 1962-1969 (2000).
21. Simon P, Kasimir MT, Seebacher G et al.: Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur. J. Cardiothorac. Surg. 23(6), 1002-1006 (2003).
22. Bechtel JF, Stierle U, Sievers HH: Fifty-two months' mean follow up of decellularized SynerGraft-treated pulmonary valve allografts. J. Heart Valve Dis. 17(1), 98-104 (2008).
23. Dohmen PM, Hauptmann S, Terytze A et al.: In-vivo repopularization of a tissue-engineered heart valve in a human subject. J. Heart Valve Dis. 16(4), 447-449 (2007).
24. Cebotari S, Lichtenberg A, Tudorache I et al.: Clinical application of tissue engineered human heart valves using autologous progenitor cells. Circulation 114(Suppl. 1), I132-I137 (2006).
25. Juthier F, Vincentelli A, Gaudric J et al.: Decellularized heart valve as a scaffold for in vivo recellularization: deleterious effects of granulocyte colony-stimulating factor. J. Thorac. Cardiovasc. Surg. 131(4), 843-852 (2006).
26. Felker GM, Milano CA, Yager JE: Outcomes with an alternate list strategy for heart transplantation. J. Heart Lung Transplant. 24(11), 1781-1786 (2005).
27. Matheny RG, Hutchison ML, Dryden PE et al.: Porcine small intestine submucosa as a pulmonary valve leaflet substitute. J. Heart Valve Dis. 9(6), 769-774 (2000).
28. Kasimir MT, Rieder E, Seebacher G et al.: Decellularization does not eliminate thrombogenicity and inflammatory stimulation in tissue-engineered porcine heart valves. J. Heart Valve Dis. 15(2), 278-286 (2006).
29. de Mel A, Jell G, Stevens MM et al.: Biofunctionalization of biomaterials for accelerated in situ endothelialization: a review. Biomacromolecules 9(11), 2969-2979 (2008).
30. Walluscheck KP, Steinhoff G, Kelm S et al.: Improved endothelial cell attachment on ePTFE vascular grafts pretreated with synthetic RGD-containing peptides. Eur. J. Vasc. Endovasc. Surg. 12(3), 321-330 (1996).
31. Blindt R, Vogt F, Astafieva I et al.: A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhbits neointimal hyperplasia by recruiting endothelial progenitor cells. J. Am. Coll. Cardiol. 47(9), 1786-1795 (2006).
32. Meinhart JG, Schense JC, Schima H et al.: Enhanced endothelial cell retention on shear-stressed synthetic vascular grafts precoated with RGD-cross-linked fibrin. Tissue Eng. 11(5-6), 887-895 (2005).
33. Rotmans JI, Heyligers JM, Verhagen HJ: In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation 112(1), 12-18 (2005).
34. Wojciechowski JC, Narasipura SD, Charles N et al.: Capture and enrichment of CD34-positive haematopoietic stem and progenitor cells from blood circulation using P-selectin in an implantable device. Br. J. Haematol. 140(6), 673-681 (2008).
35. Wu S, Liu YL, Cui B et al.: Study on decellularized porcine aortic valve/poly (3-hydroxybutyrate-co-3-hydroxyhexanoate) hybrid heart valve in sheep model. Artif. Organs 31(9), 689-697 (2007).
36. Stamm C, Khosravi A, Grabow N et al.: Biomatrix/polymer composite material for heart valve tissue engineering. Ann. Thorac. Surg. 78(6), 2084-2092 (2004).
37. Tedder ME, Liao J, Weed B: Stabilized collagen scaffolds for heart valve tissue engineering. Tissue Eng. Part A 15(6), 1257-1268 (2009).
38. Crombez M, Chevallier P, Gaudreault RC: Improving arterial prosthesis neo-endothelialization: application of a proactive VEGF construct onto PTFE surfaces. Biomaterials 26(35), 7402-7409 (2005).
39. Hristov M, Erl W, Weber PC: Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler. Thromb. Vasc. Biol. 23(7), 1185-1189 (2003).
40. Frid MG, Kale VA, Stenmark KR: Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ. Res. 90, 1189-1196 (2000).
41. Meinhart JG, Deutsch M, Fischlein T et al.: Clinical autologous in vitro endothelialization of 153 infrainguinale PTFE grafts. Ann. Thorac. Surg. 71(Suppl. 5), S327-S331 (2001).
42. Thomas AC, Campbell GR, Campbell JH: Advances in vascular tissue engineering. Cardiovasc. Pathol. 12(5), 271-276 (2003).
43. Kasimir MT, Weigel G, Sharma J et al.: The decellularized porcine heart valve matrix in tissue engineering: platelet adhesion and activation. Thromb. Haemost. 94(3), 562-567 (2005).
44. Thomas HE, Redgrave R, Cunnington MS et al.: Circulating endothelial progenitor cells exhibit diurnal variation. Arterioscler. Thromb. Vasc. Biol. 28, e21-e22 (2008).
45. Hattori K, Heissig B, Tashiro K et al.: Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells. Blood 97(11), 3354-3360 (2001).
46. Wojakowski W, Ratajczak MZ, Tendera M: Interleukin-8: more on the mechanisms of progenitor cells mobilization in acute coronary syndromes. Eur. Heart J. 27(9), 1013-1015 (2006).
47. Aicher A, Zeiher AM, Dimmeler S: Mobilizing endothelial progenitor cells. Hypertension 45(3), 321-325 (2005).
48. Hoffmann J, Groll J, Heuts J et al.: Blood cell and plasma protein repellent properties of star-PEG-modified surfaces. J. Biomater. Sci. Polym. Ed. 17(9), 985-996 (2006).
49. Wilson DS, Szostak JW: In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611- 647 (1999).
50. Nimjee SM, Rusconi CP, Sullenger BA: Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583 (2005).
51. Brody EN, Gold L: Aptamers as therapeutic and diagnostic agents. J. Biotechnol. 74, 5-13 (2000).
52. Tuerk C, Gold L: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-510 (1990).
53. Chandler AB: In vitro thrombotic coagulation of the blood; a method for producing a thrombus. Lab Invest. 7, 110-114 (1958).
54. Hoffmann J, Paul A, Harwardt M et al.: Immobilized DNA aptamers used as potent attractors for porcine endothelial precursor cells. J. Biomed. Mater. Res. A 84(3), 614-621 (2008).
55. Zilla P, Fullard L, Trescony P et al.: Glutaraldehyde detoxification of aortic wall tissue: a promising perspective for emerging bioprosthetic valve concepts. J. Heart Valve Dis. 6(5), 510-520 (1997).
56. Groll J, Haubensak W, Ameringer T et al.: Ultrathin coatings from isocyanate terminated star PEG prepolymers: patterning of proteins on the layers. Langmuir 21(7), 3076-3083 (2005).